GENT med vekst og positiv EBIT i Q2 - det er jo noe å ta med seg NewsWeb
De har jo spist av kassen hvert kvartal de siste årene, mulig vi kan nå begrave emisjonsspøkelset for en stund.
De beholder ambisjonen om 1 mrd NOK omsetning, men når det skal skje (5-7 år har de skrevet i flere år) er nå fjernet 
Får håpe de klarer snu det til positive resultat heretter. Men ikke helt overbevist når organisk vekst kun er 2%.
up 13% vs 2Q22. Revenue of MNOK 65.6 in 1H23 up 30% vs 1H22. Organic growth for the quarter was 2% in 2Q23 vs 2Q22 and 17% in 1H23 vs 1H22
Andre positive elementer:
Increased use of Cystatin C recommended in updated guidelines for clinical use, of which the proposed update from KDIGO is the most recent one, resulting in further expansion of the global market*
Confirmed value, validated by clinical trial, of GCAL for early detection of severe infections and prediction of clinical deterioration in an emergency setting
Third Party product sales increased by 112% in Q2 and 68% for H1, driven by the new fCAL® turbo contracts in Sweden and Norway
Progress NT-proBNP ? 
90% vekst for Cyst C, > 30 mnok omsetning i det historisk sett svakeste kvartalet.
Er dette starten på gjennombruddet ?
Får meg til å heve øyenbrynene ihvertfall
09:18
Infront TDN Direkt / E24
DEL
Gentian Diagnostics fikk en omsetning på 35 millioner kroner i tredje kvartal 2023, mot en omsetning på 25 millioner kroner samme periode året før.
Det fremgår av kvartalsrapporten torsdag.
Selskapet fikk et driftsresultat på minus 1,2 millioner kroner i tredje kvartal 2023, mot minus 8,7 millioner kroner samme kvartal året før.
Resultatet før skatt endte på minus 0,8 millioner kroner.
Kontantbeholdningen til selskapet ved utgangen av kvartalet var 76,4 millioner kroner.
– Den underliggende veksten er i ferd med å gå tilbake til nivåene vi så før pandemien, som vi selvfølgelig setter pris på, sier Gentian-direktør HIlja Ibert.
We are witnessing a growing demand and interest in circulating calprotectin, which we see as a testament to the biomarker’s clinical value and potential to improve patient care. In response to this heightened interest, we have expanded our global footprint by establishing partnerships with new international collaborators. We are also delighted to welcome new routine users of Gentian GCAL® Calprotectin Immunoassay, our turbidimetric plasma and serum calprotectin immunoassay, on a global scale.
Calprotectin in plasma and serum serves as a sensitive and early biomarker for detecting inflammation and inflammatory responses in infections. Elevated levels of calprotectin are released into the bloodstream during inflammation, and the concentration of calprotectin corresponds to the extent of inflammation. Its application has been documented in various conditions, encompassing both infectious and non-infectious inflammatory scenarios.
The GCAL® is the first turbidimetric assay for the quantitative measurement of calprotectin in plasma and serum intended as an aid in the detection and assessment of inflammation.
Numerous studies have demonstrated the substantial value of plasma and serum calprotectin in the detection and evaluation of infections within the emergency department (ED) and intensive care unit (ICU).
The year 2023 was marked by publications of three notable clinical studies about calprotectin in the emergency setting, using the GCAL® assay:
Karolinska University Hospital, Stockholm : This study demonstrates the feasibility of using calprotectin to aid in acute assessment and transfer decisions from the ED to the ICU or ward.
Charité University, Berlin : Preclinical results from this study, presented at ECCMID 2023, indicate the potential of calprotectin in severity assessment to predict infection, sepsis and mortality.
Health Economic Study: Exploring the predictive use of plasma calprotectin, which facilitates clinical decision making in cases of suspected sepsis, indicates that such determination has a dual impact - cost-saving and life-saving - on the healthcare system.
Building on a vast amount of scientific evidence, calprotectin is increasingly recognised and extended to daily clinical use in immunology and rheumatology departments. An official recommendation to measure S100 proteins has been incorporated into the EULAR guideline for IL-1 mediated autoinflammatory diseases, indicating a significant step towards the routine use of calprotectin measurement in the expanding field of immunology. This development anticipates a steadily increase in adoption and routine use of calprotectin measurements within clinical routine protocols.
Several noteworthy scientific publications and reviews have discussed circulating calprotectin. You will find an overview of selected literature on calprotectin on our webpage in certain focus areas:
Highlight reviews from 2023:
S100A8/A9: An emerging player in sepsis and sepsis-induced organ injury
Er ikke dette en helt rå kvartals- og årsrapport? Over 30 % vekst og betydelig økt kontantbeholdning? Er dette en ganske uoppdaget juvel, eller er det noe jeg ikke ser?
Det er absolutt mye bra.
Men kontantbeholdningen er nå høy grunnet unormalt lav arbeidskapital (ca 10 mill.). Arbeidskapitalen vil normalisere seg i 2024 og cash’en er da kanskje rundt 75 mNOK.
Ifølge regnskapet per 31.12.23 er omløpsmidler NOK 141,2 mill… Herav er kontantbeholdningen NOK 87,6 mill. Kortsiktig gjeld er NOK 24,6 mill… Arbeidskapitalen er 141,2 - 24,6 som er NOK 116,6 mill. som er veldig solid.